Dexcel is lined up to copy 1 of the blockbuster drugs on this tracker, which earned $6.4B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Dexcel's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Vyndaqel | Pfizer | Generic | 2031 | Settled Apr 2026; launch from 1 Jun 2031 | $6.4B |
Each drug page lists sources for these entries. Brand sales show the size of the market, not Dexcel's share of it.